91 related articles for article (PubMed ID: 28191543)
1. The third-time chronic myeloid leukemia in lymphoblastic crisis with ABL1 kinase mutation induced by decitabine, dexamethason combined with nilotinib and dasatinib.
Wang S; Qiao C; Zhu Y; Shen W; He G; Li J
J Transl Int Med; 2016 Dec; 4(4):182-184. PubMed ID: 28191543
[TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
5. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
6. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
7. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
8. The overwhelmingly positive response to Dasatinib of a patient with multiple blast crisis of chronic myeloid leukemia.
Xu Z; Zheng M; Wu C; Ma Y; Meng L; Zhou J; Wang Y
Int J Clin Exp Med; 2015; 8(1):1460-6. PubMed ID: 25785155
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Blast Crisis of Chronic Myeloid Leukemia Followed by Lineage Switch to B-Lymphoblastic Leukemia: A Case Report.
Liu J; Zhou Y; Yuan Q; Xiao M
Onco Targets Ther; 2020; 13():3259-3264. PubMed ID: 32368084
[TBL] [Abstract][Full Text] [Related]
10. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia.
Balducci E; Loosveld M; Rahal I; Boudjarane J; Alazard E; Missirian C; Lafage-Pochitaloff M; Michel G; Zattara H
Hematol Oncol; 2018 Feb; 36(1):344-348. PubMed ID: 28444777
[TBL] [Abstract][Full Text] [Related]
11. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
12. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
16. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
19. Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation.
Sklarz LM; Wittke C; Krohn S; GROßE-Thie C; Junghanss C; Murua Escobar H; Glaeser H
Anticancer Res; 2018 Jul; 38(7):3961-3966. PubMed ID: 29970518
[TBL] [Abstract][Full Text] [Related]
20. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
